Please see Full Prescribing Information including Medication Guide forIMFINZIandIMJUDO. What are IMFINZI and IMJUDO? Important Safety Information What is the most important information I should know about IMFINZI®(durvalumab) and IMJUDO®(tremelimumab-actl)?
Please see Full Prescribing Information including Medication Guide forIMFINZIandIMJUDO. You mayreport side effects related to AstraZeneca products. BTCs=biliary tract cancers; CI=confidence interval; CT=chemotherapy; gem-cis=gemcitabine-cisplatin; HCC=hepatocellular carcinoma; mNSCLC=metastatic non-small ce...
IMJUDO is approved for use when prescribed with IMFINZI for specific indications and is not to be approved as a monotherapy.Please refer to the full Prescribing Information, including Patient Information, forIMFINZIandIMJUDOwhen prescribing these products. For more information on coding, reimbursement,...
Please see Full Prescribing Information including Medication Guide forIMFINZIandIMJUDO. What are IMFINZI and IMJUDO? Important Safety Information What is the most important information I should know about IMFINZI®(durvalumab) and IMJUDO®(tremelimumab-actl)?
药店国别:产地国家:美国处方药:是所属类别:50毫克/毫升 2.4毫升/瓶包装规格:50毫克/毫升 2.4毫升/瓶计价单位:瓶生产厂家中文参考译名:生产厂家英文名:ASTRAZENECA PLP原产地英文商品名:IMFINZI 50MG/ML 2.4ML SDV AZ 1/EA原产地英文药品名:DURVALUMAB中文参考商品译名:IMFINZI注射溶液 50毫克/毫升 2.4毫升/瓶中文...
Full size image The dose-expansion phase comprised three arms. Patients enrolled in Arm 1 received gefitinib 250 mg QD plus durvalumab 10 mg/kg IV Q2W. Arm 1 was intended to address whether concurrent gefitinib and durvalumab could achieve a more durable response than historical gefitinib mo...
Full size image Supplementary file1 Video (MP4 8106 kb) CASPIAN enrolled patients (n =805) aged ≥ 18 years (≥ 20 years in Japan) with treatment-naïve histologically or cytologically documented ES-SCLC, a WHO performance status score of 0 or 1, measurable disease according to Response Ev...
You have full access to thisopen accessarticle DrugsAims and scopeSubmit manuscript Yahiya Y. Syed 8500Accesses 119Citations Explore all metrics AnErratumto this article was published on 10 October 2017 This article has beenupdated Abstract